MONDAY, June 15 (HealthDay News) -- Tolterodine extended release, along with a behavioral intervention, may lead to treatment satisfaction in patients with overactive bladder who were previously dissatisfied with antimuscarinics, according to research published in the June issue of the Journal of Urology.
Carl G. Klutke, M.D., of the Washington University School of Medicine in St. Louis, and colleagues analyzed data from 416 adults with overactive bladder symptoms who were previously dissatisfied with tolterodine or other antimuscarinics. During the 16-week study, patients were given tolterodine extended release along with a self-administered educational pamphlet. If they were dissatisfied midway through, they were given individualized behavioral intervention with a clinician.
At week eight, 53 percent reported that they were very satisfied with the treatment; at that time, 13 percent of patients opted for the individualized intervention, the researchers found. At week 16, 64 percent reported being very satisfied and 91 percent reported being at least a little satisfied.
"Many patients with overactive bladder may benefit from a simple, self-administered behavioral intervention using patient education materials and verbal reinforcement, in addition to antimuscarinic medication. This approach introduces little cost or burden on the clinician aside from the time needed to introduce the behavioral intervention and it is easily implemented and well suited to primary and specialty care settings," the authors write.
The study was supported by Pfizer. Several co-authors reported financial interests in or other relationships with Pfizer and other pharmaceutical companies.
Abstract
Full Text (subscription or payment may be required)
